HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia

Leukemia

Volumn 21, Issue 1, 2007, Pages 129-135

  Herr, A L ^a   Labopin, M ^b   Blaise, D ^c   Milpied, N ^d   Potter, M ^e   Michallet, M ^f   Heit, W ^g   Ferrara, F ^h   Esteve, J ⁱ   Arcese, W ^j   Ehninger, G ^k   Rowe, J M ^l   Kobbe, G ^m   Rosselet, A ^a   Bunjes, D ⁿ   Rio, B ^o   Brune, M ^p   Nagler, A ^q   Gorin, N C ^b   Frassoni, F ^r   Rocha, V ^s   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g Eye Hospital   (Germany)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l RAMBAM MEDICAL CENTER   (Israel)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ Medizinische Klinik und Poliklinik   (Germany)

^o HÔTEL DIEU   (France)

^p SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^q TEL AVIV UNIVERSITY   (Israel)

^r UNIVERSITY OF GENOA   (Italy)

^s SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HLA ANTIGEN; LYMPHOCYTE ANTIBODY; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGISTRY; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ELDERLY CARE; EUROPE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEALTH CARE ORGANIZATION; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SIBLING; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 33845573825     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404461     Document Type: Article

References (30)

1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. ASH Education Program Book 2004, 98-117.
2. Estey EH. How I treat older patients with AML. Blood 2000; 96: 1670-1673.
3. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443-450.
4. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglund M, Karlsson K et al. Attitude towards remission induction for elderly patients with acute myeloid leukaemia influences survival. Leukaemia 2006; 20: 42-47.
5. Gorin NC. Autologous stem cell transplantation in acute myeloid leukemia. Blood 1998; 92: 1073-1090.
6. Breems DA, Löwenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005; 130: 825-833.
7. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-223.
8. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
9. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study. Leukemia 1996; 10: 1874-1882.
10. Suciu S, Mandelli F, de Witte T, Zottoun R, Gallo E, Labar B et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232-1240.
11. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57-60.
12. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang SY et al. Allogeneic hematopoietic cell transplantation (HCT) following reduced intensity conditioning in patients with acute leukemias. Crit Rev Oncol Hematol 2005; 56: 275-281.
13. Slavin S, Nagler A, Naparstek Y, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
14. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
15. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplanatation in patients with acute myeloid leukemia: A donor versus no donor comparison. Leukemia 2005; 19: 916-920.
16. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing highdose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
17. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1484-1840.
18. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052-3059.
19. Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089-1095.
20. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shiruzu JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453.
21. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
22. Shimoni A, Kröger N, Yabelina T, Ayuk F, ardan I, Yeshurun M et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: Older age is no longer a contraindication when using reduced intensity conditioning. Leukaemia 2005; 19: 7-12.
23. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-1814.
24. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
26. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
27. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 665-706.
28. Cox DR. Regression models and life tables. J Roy Stat Soc. 1972; 34: 187-202.
29. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of American Statistical Association 1999; 94: 496-509.
30. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.